Scarica l'app Stockscreener
5.14
11.26%
0.52
Pre-mercato:
5.40
0.26
+5.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Precedente Chiudi:
$4.62
Aprire:
$4.71
Volume 24 ore:
97,847
Relative Volume:
0.48
Capitalizzazione di mercato:
$28.86M
Reddito:
$7.97M
Utile/perdita netta:
$-75.74M
Rapporto P/E:
-0.2117
EPS:
-24.2853
Flusso di cassa netto:
$-85.33M
1 W Prestazione:
+8.90%
1M Prestazione:
-52.19%
6M Prestazione:
-29.97%
1 anno Prestazione:
-74.33%
Intervallo 1D:
$4.55
$5.19
Intervallo di 1 settimana:
$4.33
$5.19
Portata 52W:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Nome
Aligos Therapeutics Inc
Settore
Industria
Telefono
(800) 466-6059
Indirizzo
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Confronta ALGS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.14 | 28.86M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-19 | Iniziato | H.C. Wainwright | Buy |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-09 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Ripresa | Piper Sandler | Overweight |
| 2020-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Iniziato | JP Morgan | Overweight |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
When the Price of (ALGS) Talks, People Listen - news.stocktradersdaily.com
ALGS stock touches 52-week low at $4.21 amid market challenges By Investing.com - Investing.com South Africa
ALGS stock touches 52-week low at $4.21 amid market challenges - Investing.com India
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% - MSN
(ALGS) Investment Analysis - news.stocktradersdaily.com
ALGS stock touches 52-week low at $6.71 amid market challenges By Investing.com - Investing.com South Africa
ALGS stock touches 52-week low at $6.71 amid market challenges - Investing.com
Charles Schwab Investment Management Inc. Buys 2,306 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Receives “Buy” Rating from HC Wainwright - Defense World
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - MSN
(ALGS) Long Term Investment Analysis - news.stocktradersdaily.com
Aligos Therapeutics Presents Positive Data at APASL 2025 - The Manila Times
Clinical Trial Success: Aligos' Dual Breakthroughs in Liver Disease Show 100% Efficacy - Stock Titan
Ten option delistings on March 24th - TipRanks
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) - Armenian Reporter
ALG-097558 confirmed as an effective pan-coronavirus strategy - BioWorld MedTech
Learn to Evaluate (ALGS) using the Charts - news.stocktradersdaily.com
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics Expands Team with Strategic Stock Option Package - Stock Titan
HC Wainwright Issues Negative Outlook for ALGS Earnings - Defense World
Financial Comparison: Achilles Therapeutics (NASDAQ:ACHL) vs. Aligos Therapeutics (NASDAQ:ALGS) - Defense World
H.C. Wainwright cuts Aligos stock target to $70, maintains Buy By Investing.com - Investing.com Australia
H.C. Wainwright cuts Aligos stock target to $70, maintains Buy - Investing.com India
Aligos Therapeutics (NASDAQ:ALGS) Price Target Lowered to $70.00 at HC Wainwright - Defense World
Aligos Therapeutics Faces Challenges in Developing Hepatitis B Treatments Amidst Industry Competition - TipRanks
Aligos Therapeutics Advances Pipeline Amid Financial Challenges - TipRanks
Aligos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aligos Therapeutics reports fourth-quarter and full-year 2024 results -March 10, 2025 at 10:48 am EDT - Marketscreener.com
ALIGOS THERAPEUTICS Earnings Results: $ALGS Reports Quarterly Earnings - Nasdaq
Aligos Therapeutics reports Q4 EPS ($13.08) vs ($5.50) last year - TipRanks
Aligos Therapeutics, Inc. SEC 10-K Report - TradingView
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Aligos Q4 Earnings: $105M Raise Backs Promising HBV Drug Results - StockTitan
Earnings Scheduled For March 10, 2025 - Benzinga
Aligos Therapeutics (ALGS) to Release Earnings on Monday - The AM Reporter
Aligos Therapeutics (ALGS) to Release Quarterly Earnings on Monday - Defense World
ALIGOS THERAPEUTICS Earnings Preview: Recent $ALGS Insider Trading, Hedge Fund Activity, and More - Nasdaq
How the (ALGS) price action is used to our Advantage - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Growth in Short Interest - The AM Reporter
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 23.7% in February - Defense World
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025 - The Manila Times
Will Aligos Therapeutics Q4 Results Reveal Progress in Liver Disease Pipeline? - Stock Titan
Critical Comparison: Editas Medicine (NASDAQ:EDIT) vs. Aligos Therapeutics (NASDAQ:ALGS) - The AM Reporter
Reviewing Aligos Therapeutics (NASDAQ:ALGS) & Editas Medicine (NASDAQ:EDIT) - Defense World
(ALGS) Trading Report - news.stocktradersdaily.com
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Decline in Short Interest - MarketBeat
Aligos Therapeutics looks to raise $105 million in private placement - MSN
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Down 13.2% in January - Defense World
Aligos Therapeutics Announces $105 Million Private Placement FinancingAligos Therapeutics, Inc. (NASDAQ: ALGS) recently disclosed a Securities Purchase Agreement engagement entailing a Private Placement offering. The agreement includes the issuan - Defense World
Aligos Therapeutics, Inc. announced that it expects to receive $105.003206 million in funding - Marketscreener.com
Aligos Therapeutics secures $105 million in private placement By Investing.com - Investing.com Canada
Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):